Nothing said here yet.
to join the conversation.
| Greenleaf PeterDirector | Sell | 797 | $16.9K | Fri, Oct 2 |
| Pauls MatthewDirector | Sell | 786 | $16.5K | Fri, Oct 2 |
| Friedberg Ezra MDirector | Sell | 558 | $11.6K | Fri, Oct 2 |
The average analyst fair value estimate for Pelthos Therapeutics has shifted from US$59.80 to about US$51.71 per share, which marks a moderate reset in price targets.
ZELSUVMI revenue jumped 45% as prescriber count surged and new PBM contracts drove adoption.
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment’s July 2025 commercial launch.
Strong prescription growth and expanding prescriber base drive momentum, while company navigates inventory adjustments and prepares for upcoming launches.
Moby summary of Pelthos Therapeutics Inc.'s Q2 2026 earnings call
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025 Management will host a conference call today, August 13, 2026, at 8:30 a.m.
Company to hold a conference call at 8:30 a.m. ETDURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc.
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m.